India-US trade deal: Which Indian goods will face zero tariffs in America? Piyush Goyal lists out

India and the US have reached a trade agreement that cuts the reciprocal tariff rate to 18% (down from 50%) and grants zero-duty access for a wide range of Indian exports including generic pharmaceuticals, gems & diamonds, aircraft parts, smartphones, spices, select nuts, fruits and some bakery products. The accord includes US concessions such as Section 232 exemptions for aircraft parts, a tariff-rate quota on auto parts and negotiated outcomes on generics, and New Delhi signalled intent to buy roughly $500 billion of US goods over five years (energy, aircraft and parts, precious metals, tech products and coking coal) while protecting sensitive Indian agricultural and dairy sectors and barring GM imports.

Analysis

Market structure: Zero tariffs for Indian gems, generics, aircraft parts and select agri/processed foods materially increases price competitiveness vs China/ASEAN in US markets and should shift market share over 12–36 months toward Indian suppliers. Expect sharper export volume growth in regulated generics (potential +10–30% USD flow over 2–3 years) and jewellery/diamond processing margins to expand while incumbents in SE Asia face margin pressure. Cross-asset: INR should see appreciation pressure (potential 1–3% over 3–6 months), supporting Indian sovereign credit and compressing CDS spreads; modest upward pressure on US metallurgical coal and LNG contract prices from India’s $500bn import intent boosts related energy equities.

Risks & timing: Tail risks include deal non-ratification, US political/legal challenges, or Indian supply-side bottlenecks (FDA approvals, capacity constraints) that could wipe initial gains — probability 15–25% in next 6 months but high impact. Immediate (days–weeks): market repricing and FX moves; short-term (1–6 months): order announcements and export contracts; long-term (1–5 years): structural shift in supply chains and capital expenditure in India’s manufacturing & pharma. Hidden dependencies: India must scale compliance (US FDA), cold chain and shipping capacity — failure delays value realization.

Trade implications: Preferred exposures are exporters and contract manufacturers (broad India ETF INDA, select ADRs) and select Indian electronics and generic pharma names; use options to cap downside. Pair trades: long Indian generics (RDY ADR) vs short US commodity generics with weaker pipelines; FX play: buy INR via forwards or buy puts on USD/INR. Catalysts to watch: signed tariff schedules, tranche export orders, US import data and India’s purchase contracts (aircraft/energy) within 30–90 days.

Contrarian view: Consensus underestimates capex/time needed to scale FDA-compliant API/finished-dose production — early winners may be logistics, testing labs, and contract manufacturers rather than headline pharma bellwethers. Reaction may be overdone in short term; a disciplined entry with 3–6 month proof points (shipment data, US customs records) avoids overpaying. Unintended consequence: accelerated food/fruit exports could tighten domestic supply and stoke inflation, creating political pushback that could alter liberalization timelines.

Key Decisions for Investors

• Establish a 2–3% portfolio position in INDA (iShares MSCI India ETF) over 2–4 weeks, scale in at 0.5% tranches; target 12–18% upside in 12 months if export flows accelerate, stop-loss at -10%.
• Initiate a 1–1.5% directional exposure to RDY (Dr. Reddy's ADR) via a 6–12 month call spread (buy ATM 12-month call, sell 10–15% OTM call) to capture US generics tailwind while limiting premium outlay; liquidate if no material US contract wins or shipment increases within 6 months.
• Buy a 1–2% equity position in DIXON.NS (Indian contract electronics manufacturer) or similar domestic EMS play within 30 days to capture smartphone/consumer electronics export growth; exit if QoQ export revenue does not rise >10% within two quarters.
• Deploy a tactical 0.5–1% FX allocation: purchase INR via a 3-month forward or structured USD/INR put spread (cap cost) to capture an expected 1–3% INR appreciation; unwind on move stronger than -3% or if deal ratification stalls >90 days.